Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Sep 2024
Responses to pirtobrutinib observed in patients with previously treated disease
Read Full NewsClinical Forum Weighs in: Biologic Selection in Asthma and COPD
Treatable Traits in Asthma and COPD: Clinical Forum Perspectives
Biologic Access in Asthma and COPD: Clinical Forum Perspectives
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
1.
The Truth About Apple AirPods
2.
Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A
3.
Can taking vitamin D supplements every day lower the mortality rate from cancer?
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC
1.
Bone Marrow Fatty Acid Utilization During Healthy Aging
2.
Clonal Hematopoiesis and Thrombotic Risk Beyond Cancer: A Comprehensive Review for Clinicians
3.
Oncology Team Communication Training for Clinical Learners
4.
Liquid Biopsy in Cancer Screening: An Evidence-Based Review for Clinicians
5.
Diagnostic Evaluation of Iron Deficiency Anemia in Adults
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge